Corcept
Menlo Park, California, United States · Biotechnology, Biotechnology Research, Health Care
Leading the field in the discovery of drugs that modulate the effects of cortisol. The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess
Key facts
- Headquarters
- Menlo Park, California, United States
- Employees
- 824
- Industries
- Biotechnology, Biotechnology Research, Health Care
- Status
- Public (CORT)
- Website
- corcept.com
- Company page
Recent activity at Corcept
Leadership
- Sean Maduck, President
- Roberto Vieira, President
- Monica Tellado, President
Verified email and direct lines for Corcept’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Corcept files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Corcept in the news
- Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It - Seeking Alpha (Jul 31, 2026)
- Corcept Therapeutics Stock Shines at New All-Time Highs Despite Its Valuation - Barchart.com (Aug 05, 2026)
- Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears - BioSpace (May 01, 2026)
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - Business Wire (Jul 29, 2026)
- Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? - Yahoo Finance (Mar 05, 2026)
- Dazucorilant Shows 2-Year Survival Benefit in Phase 2 ALS Trial Despite Missing Primary End Point - NeurologyLive (May 05, 2026)
- Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant) - Via TT (Sep 18, 2026)
- FDA declines to approve Corcept's rare disorder drug - pharmaphorum (Jan 02, 2026)
Companies similar to Corcept
- Compugen · Biotechnology, Biotechnology Research, Health Care, Medical, Therapeutics
- Glaukos Corporation · Biotechnology, Health Care, Medical, Therapeutics
- Vectura Group Limited · Biotechnology, Health Care, Medical, Therapeutics
- HARMONY BIOSCIENCES · Biotechnology, Health Care, Medical, Therapeutics
- Wave Life Sciences · Biotechnology, Health Care, Medical, Therapeutics
About Corcept: questions and answers
What does Corcept do?
Leading the field in the discovery of drugs that modulate the effects of cortisol. The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess
Where is Corcept headquartered?
Corcept is headquartered in Menlo Park, California, United States.
How many employees does Corcept have?
Corcept has about 824 employees.
Who leads Corcept?
Sean Maduck is a President at Corcept.
What is the latest news on Corcept?
On Sep 23, 2026, Corcept Therapeutics Announces Resignation of President Sean Maduck
Is Corcept a public company?
Yes. Corcept is publicly traded under the ticker CORT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy